IHC Stands For: Immunohistochemistry Explained

What IHC Stands For and Why It Matters

IHC stands for immunohistochemistry. It is a laboratory technique pathologists use to visualize specific proteins in cells and tissues. By binding antibodies to target molecules, IHC produces a stain that reveals whether a protein is present, absent, or overexpressed. This information helps diagnose diseases, classify tumors, and guide treatment decisions. The method sits at the intersection of anatomy and molecular biology, giving clinicians a window into tissue architecture and protein expression at the same time.

How Immunohistochemistry Works

The IHC process begins with a thin section of preserved tissue, usually fixed in formalin and embedded in paraffin. Technicians slice the sample onto slides, deparaffinize it, and apply a series of chemical steps to make target proteins accessible. A primary antibody, chosen for its ability to bind a specific protein, is applied to the slide. After washing away unbound antibody, a secondary antibody linked to an enzyme or fluorescent label is added. That label produces a visible signal, typically a brown or red deposit, at the site of the target protein. A pathologist then examines the stained slide under a microscope.

Key Reagents in the IHC Workflow

• Primary antibody: Recognizes and binds the target protein directly.
• Secondary antibody: Carries the detection label and amplifies the signal.
• Chromogen or fluorophore: Generates the visible stain or fluorescent signal.
• Counterstain: Provides contrast, usually highlighting cell nuclei.

Common Clinical Applications

IHC is indispensable in oncology. It identifies protein markers that distinguish one cancer type from another. For example, estrogen receptor (ER) and progesterone receptor (PR) staining determines whether a breast cancer patient is a candidate for hormone therapy. Human epidermal growth factor receptor 2 (HER2) status, assessed by IHC, guides decisions about targeted therapies like trastuzumab. In lymphoma diagnosis, markers such as CD20, CD3, and Ki-67 help classify the subtype and estimate how quickly the tumor might grow. Beyond cancer, IHC detects infectious agents, identifies autoimmune tissue damage, and confirms the origin of metastatic tumors when the primary site is unknown.

Strengths and Limitations

IHC offers several advantages. It works on routine formalin-fixed, paraffin-embedded tissue, preserving the cellular context pathologists need. Results are relatively fast and affordable compared to many molecular tests. The technique can be semi-quantitative, with pathologists scoring staining intensity and the percentage of positive cells.

However, IHC has limitations. Antibody specificity varies, and cross-reactivity can produce false positives. Pre-analytical factors, including tissue fixation time and processing conditions, affect antigen preservation and can weaken staining. Scoring is inherently subjective, which is why standardized scoring systems and external quality assurance programs exist. In cases where a protein is expressed at low levels, IHC may miss it, and molecular methods such as PCR or sequencing may be needed as a follow-up.

IHC Versus Other Diagnostic Methods

IHC is often compared with molecular pathology techniques. While PCR and next-generation sequencing detect genetic mutations and gene expression at the nucleic acid level, IHC measures the protein products those genes encode. Some proteins, such as PD-L1, are routinely assessed by IHC because the staining pattern correlates with therapeutic response. Other targets, like certain gene fusions, are better evaluated by fluorescence in situ hybridization (FISH) or RNA-based assays. In practice, pathologists frequently use IHC alongside molecular tests to build a complete diagnostic picture.

What IHC Results Mean for Patients

A positive IHC result means the target protein was detected in the tissue sample. A negative result means it was not detected, though low-level expression can sometimes fall below the assay's detection threshold. The pathologist reports the staining pattern, intensity, and proportion of positive cells, often using a scoring system such as Allred or H-score. Oncologists interpret these results together with imaging, clinical history, and other laboratory data to assign a diagnosis and select a treatment plan.

Emerging Advances in Immunohistochemistry

Automated staining platforms have improved consistency and throughput in clinical labs. Digital pathology systems allow whole-slide imaging and remote review, making IHC results accessible across institutions. Multiplex IHC, which stains for two or more markers on the same tissue section, is gaining traction because it reveals co-expression patterns that single-marker stains cannot. These advances are expanding the diagnostic utility of IHC while reducing turnaround time and variability between labs.